

Note: PDFs are available upon request from Dan, email: [dan@jba-cht.com](mailto:dan@jba-cht.com)

#### STDs

- CA DOH STD. Region IX Guidelines for Gonorrhea Screenings and Diagnostic Testing Among Women in Family Planning and Primary Care Settings. 30 September 2006.  
[http://www.centerforhealthtraining.org/download/R9\\_GC\\_Guidelines\\_06.pdf](http://www.centerforhealthtraining.org/download/R9_GC_Guidelines_06.pdf)
- CDC, National Center for HIV/AIDS, Viral Hepatitis STD, and TB Prevention. 2006 Disease Profile. CDC. 2008. <http://www.cdc.gov/nchhstp/Publications/>
- CDC. Regional Data Codebook: Chlamydia Prevalence Monitoring Project Infertility Prevention Project. CDC. January 2008. *<pdf only>*
- Hewett., PC., Mensch, BS., de A. Ribeiro, MC., et al. Practice of Epidemiology: Using Sexually Transmitted Infection Biomarkers to Validate Reporting of Sexual Behavior within a Randomised, Experimental Evaluation of Interviewing Methods. Am J Epid. 4 June 2008. *<pdf only>*
- Hutton, HE., McCaul, ME., Santora, PB., et al. Relationship Between Recent Alcohol Use and Sexual Behaviors: Gender Differences Among Sexually Transmitted Disease Clinic. Alcohol Clin Exp Res. 2008. *<pdf only>*
- Novak, DS. SEE Coordinators Colleague Letter. CDC. September 2008. *<pdf only>*
- Sharpton, T., Validation of the Genprobe Aptima Combo 2 Assay for the Detection of *C. trachomatis* and *N. gonorrhoeae* from Rectal and Pharyngeal Swabs. Utah PH Labs. *<pdf only>*
- Weinbaum, CM., Williams, I., Mast, EE., et al. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. MMWR. 19 September 2008.  
[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm?s\\_cid=rr5708a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm?s_cid=rr5708a1_e)

#### HIV

- Bailey, RC., Egesah, O., Rosenberg, S. Male circumcision for HIV prevention: a prospective study of complications in clinical and traditional settings in Bungoma, Kenya. BWHO. September 2008. *<pdf only>*
- Bartlett, JG., Branson, BM., Fenton K., et al. Opt-Out Testing for Human Immunodeficiency Virus in the United States: Progress and Challenges. JAMA. 27 August 2008. *<pdf only>*
- Bertozzi, SM., Laga, M., Bautist-Arredondo, S., et al. Making HIV prevention programmes work. Lancet. 6 September 2008. *<pdf only>*
- CDC. Subpopulation Estimates from the HIV Incidence Surveillance System- United States 2006. MMWR. 12 September 2008.  
[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5736a1.htm?s\\_cid=mm5736a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5736a1.htm?s_cid=mm5736a1_e)
- Coates, TJ., Richter, L., Caceres, C. HIV Prevention 3- Behavioural strategies to reduce HIV transmission: how to make them work better. The Lancet. 23 August 2008. *<pdf only>*
- Gable, L., Gostin, LO., Hodge, JG. HIV/AIDS, Reproductive and Sexual Health, and the Law. Am J PH. October 2008. *<pdf only>*

- Garenne, M. Long-term population effect of male circumcision in generalized HIV epidemics in sub-Saharan Africa. AJAR. 2008. <pdf only>
- Gupta, GR., Parkhurst, JO., Ogden, JA., et al. Structural Approaches to HIV prevention. Lancet. 6 August 2008. <pdf only>
- Horton, R., Das, P. Putting prevention at the forefront of HIV/AIDS. The Lancet. 9 August 2008. <pdf only>
- IUSTI. Africa English Newsletter. IUSTI. July 2008. <pdf only>
- Jarrin, I., Geskus, R., Bhaskarann, K., et al. Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. Am J Epid. 28 July 2008. <pdf only>
- Johnston, MI., Fauci, AS. An HIV Vaccine- Challenges and Prospects. NEJM. 28 August 2008. <pdf only>
- Merson, MH., O'Malley, J., Serwadda, D., et al. HIV Prevention 1- The history and challenge of HIV prevention. The Lancet. August 2008. <pdf only>
- Piot, P., Bartos, M., Larson, H., et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 6 September 2008. <pdf only>
- Steinbrook, R. The AIDS Epidemic- A Progress Report from Mexico City. NEJM. 28 August 2008. <pdf only>
- Stringer, E., Antonsen, E. Hormonal Contraception and HIV Disease Progression. CID. 1 October 2008. <pdf only>
- Wilson, DP., Coplan, PM., Wainberg, MA., et al. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. PNAS. 15 July 2008. <pdf only>

#### FP

- Bethesda, MD. The Important of Self-Obtained Vaginal Specimens for Detection of Sexually Transmitted Infections. DWG. 27 June 2006. <pdf only>
- Carozzi, F., Confortini, M., Dalla Palma, P., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet. 9 September 2008. <pdf only>
- Castle, PE. Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening. Am J Epid. 15 May 2008. <pdf only>
- Brotman, RM., Klebanoff, MA., Nansel, TR., et al. A Longitudinal Study of Vaginal Douching and Bacterial Vaginosis- A Marginal Structural Modeling Analysis. Am J Epid. 24 March 2008. <pdf only>
- Goldstein, MA. Human Papillomavirus Vaccine in Males. NEJM. 21 August 2008. <pdf only>
- Haug, CJ. Human Papillomavirus Vaccination- Reasons for Caution. NEJM. 21 August 2008. <pdf only>
- Jit, M., Choi, YH., Edmunds, WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 8 August 2008. <pdf only>

- Kim, JJ., Goldie, SJ. Health and Economic Implications of HPV Vaccination in the United States. NEJM. 21 August 2008. <pdf only>
- Koshiol, J., Polle, C., Chu, H., et al. Response to Invited Commentary: The Authors Respond to 'HPV Persistence and Persistence and Cervical Cancer Screening'. Am J Epid. 15 May 2008. <pdf only>
- Koshiol, J., Lindsay, L., Pimenta, JM., et al. Persistent Human Papillomavirus infection and Cervical Neoplasia: A systematic Review and Meta-Analysis. Am J Epid. 15 May 2008. <pdf only>
- Leyland, E. Human Papillomavirus vaccination: stabbing in the dark? The Lancet. 23 August 2008. <pdf only>
- Mark, KE., Wald, A., Magaret, AS., et al. Rapidly Cleared Episodes of Herpes Simplex Virus Reactivation in Immunocompetent Adults. JID. 15 October 2008. <pdf only>
- Manlove, J., Ikramullah, E., Terry-Humen, E. Condom Use and Consistency Among Male Adolescents in the United States. Jour Adol Hlth. 20 March 2008. <pdf only>
- Martino, SC., Elliott, MN., Collins, RL., et al. Virginity Pledges Among the Willing: Delays in First Intercourse and Consistency of Condom Use. Jour Adol Hlth. 2008. <pdf only>
- Mertz, GJ. Asymptomatic Shedding of Herpes Simplex Virus 1 and 2: Implications for Prevention of Transmission. JID. 15 October 2008. <pdf only>
- Santelli, JS. Medical Accuracy in Sexuality Education: Ideology and the Scientific Process. Am J PH. October 2008. <pdf only>
- Sonenstein, FL. Can We Afford to Be Complacent About Teens' Use of Condoms? Jour Adol Hlth. 2008. <pdf only>
- Sycuro, LK., Xi, LF., Hughes, JP., et al Persistence of Genital Human Papillomavirus Infections in a Long-Term Follow-Up Study of Female University Students. JID. 1 October 2008. <pdf only>

#### Other Resources

- NICWA. State Fact Sheets. NICWA 2008. <http://www.nicwa.org/states/>
- Ogunwole, S. We the People: American Indians and Alaska Natives in the United States- Census 2000 Special Reports. US Census Bureau. February 2006. <http://www.census.gov/prod/2006pubs/censr-28.pdf>
- Treadwell, H. Thro' Many Dangers, Toils, and Snares, We have Already Come. APHA.2008. <pdf only>
- UBC. UBC Wins Prestigious \$1 Million NIH Grant for Chlamydia Vaccine Research. UBC Public Affairs.11 July 2008. <http://www.publicaffairs.ubc.ca/media/releases/2008/mr-08-089.html>
- UIHC. 2007 Urban Indian Health Commission Report. UIHC. <http://www.uihi.net/UIHC/default.aspx>
- Warnecke, RB., Oh, A., Breen, N., et al. Approaching Health Disparities from a Population Perspective: The National Institutes of Health Centers for Population Health and Health Disparities. Am J PH. September 2008. <pdf only>

Journal/ Articles for September 2008

- WHO Commission on Social Determinants of Health. Closing the gap in a generation: Health equity through action on the social determinants of health. WHO 2008. [http://www.who.int/social\\_determinants/final\\_report/en/index.html](http://www.who.int/social_determinants/final_report/en/index.html)



September 25, 2008

Dear Syphilis Elimination Coordinators:

We have reached the end of the summer and begun the 4<sup>th</sup> and final quarter of 2008. We hope this newsletter finds you well and pleased with a productive year. This edition of the quarterly Dear SEE Coordinators Letter brings with it important information, updates, and resources to aid your syphilis elimination and STD prevention activities.



**The Syphilis Elimination Unit Has Grown**

DSTDP's Syphilis Elimination Unit is now the *Syphilis Elimination and STD Disparities Unit*. In addition to the Syphilis Elimination Coordination Team, the unit now includes the Tuskegee Benefits Program and the new STD Disparities Coordination Team.

**The New Syphilis Epidemiologist has Joined the Division**

DSTDP recently welcomed John Su, MD, PhD, MPH as the new Syphilis Epidemiologist for the Surveillance and Special Studies Team of the Epidemiology and Surveillance Branch. John's role in the Syphilis Elimination Effort is critical as his task is to remain abreast of populations affected by syphilis in the U.S. and identify trends, disparities, emerging populations, and data quality assurance issues. With the help of the Syphilis Data Sharing Group, such information is shared with the division, most frequently with program consultants and the Program and Training Branch. John is also a Commissioned Corps officer and prior to joining the CDC, he worked two years with the Texas Department of State Health Services. Please join us in welcoming John Su to the Division!

**New Public Information Resources Posted at [STD Prevention Online \(STDPO\)](#)**

In addition to the continuing epidemic of P&S syphilis among men who have sex with men, provisional data for 2007 and 2008 suggest substantial increases in P&S syphilis among women, particularly in the South, and among African American women. We invite you to visit the [resource](#) section on STDPO for a link to radio public service announcements designed to target African American heterosexual populations. Developed as part of the [SEE Community Mobilization Toolkits](#) text of this PSA and other materials are available for free download and can be useful for local intervention efforts.



Additionally, STDPO provides members with free access to *Sexually Transmitted Infections* including free downloads of full articles. All SE Coordinators are especially encouraged to join this networking site to receive important updates, information about evidence-based approaches, and lessons learned from their colleagues from across the country.

**New Internet Partner Services Data Elements**

The SE Unit has been working closely with the Statistics and Data Management Branch, Behavioral Interventions and Research Branch, and select project areas that perform Internet partner services to develop Internet-related data elements to be incorporated in the next STD\*MIS version 5.0 this Fall. Draft elements being considered include new fields to store Internet screen name or member ID, Internet site, and outcomes of the Internet intervention. In addition, a new report feature is being developed that will allow programs to determine how many original patients met partners on the Internet and the number of Internet partners elicited and informed of exposure. A special thanks to the Washington, DC and Massachusetts Internet staffs whose field experiences helped shape this new national data collection system. This new system will allow consistent collection of Internet-related activities across project areas. Plans are also underway to update the [National Guidelines for Internet-based STD and HIV Prevention](#) with these elements.

**CDC-Developed Resources and Updates**

- [\*\*MMWR – Syphilis Testing Algorithms\*\*](#)  
CDC reviewed the testing algorithms and test interpretations provided by four laboratories in New York City to assess how clinical laboratories are addressing concerns that arise from the use of treponemal test for initial screening.
- [\*\*NCHHSTP Announced New HIV Estimates for the United States\*\*](#)  
Findings were published in a special HIV/AIDS issue of the Journal of the American Medical Association (JAMA) and show the estimated number of new HIV infections that occurred in 2006.
- [\*\*2009 Guidance for Syphilis Elimination Effort Evidence-based Action Planning\*\*](#)  
Updated guidance for the development of an SE EBAP for interventions that will facilitate gathering information and tracking resources, and provide a framework for ongoing evaluation.
- [\*\*HPV and Pap Test Patient Resource\*\*](#)  
This booklet is for women who got screened for cervical cancer with a Pap test and an HPV test. It will help answer common questions about cervical cancer, HPV, and their test results.
- [\*\*Dear SEE Coordinator's Letters\*\*](#)  
This edition and all previous letters since 2005 are now available online.

**Additional Resources**

- [\*\*Syphilis Prevention and Management Web Conferences\*\*](#)  
In September 2008, Dr. Jeff Klausner, San Francisco STD Program Director, began conducting a series of monthly web conferences focusing on syphilis prevention and management in conjunction with CSI Medical Education. If you have any questions, please contact Dr. Klausner at (415) 355-2000.
- [\*\*Safe in the City\*\*](#)  
*Safe in the City* is a 23-minute HIV/STD prevention video designed for STD clinics that can be easily integrated into the clinic waiting room, requires very little staff time to set up with no disruption to clinic flow, and requires no counseling or small-group facilitation.

**Upcoming Conferences**

- [\*\*National Coalition of STD Directors \(NCSO\) 2008 Annual Meeting\*\*](#)  
This year's meeting, "STD Services at the Crossroads: *Many Lands, Many Peoples, Many Roads*", will be held October 20-24, 2008 in Phoenix, Arizona.
- [\*\*2009 ISSTD Meeting\*\*](#)  
The 18th meeting of the ISSTD, together with the BASHH meeting, will take place at The Queen Elizabeth II Conference Centre, Westminster, London, United Kingdom from June 28 – July 1, 2009.



As always, should you have any further questions or suggestions we are eager to hear from you. Please contact Jo Valentine directly at (404) 639-8366 or via electronic mail at [jvalentine@cdc.gov](mailto:jvalentine@cdc.gov).

The CDC Syphilis Elimination Effort Coordinating Team



**Regional Data Codebook: Chlamydia Prevalence Monitoring Project  
Infertility Prevention Project  
January 2008**

**I. National Screening Criteria**

**Chlamydia:**

CDC\* recommends screening:

- All sexually-active females aged  $\leq 25$  years annually
- Sexually-active females aged  $\geq 26$  years with risk factors (e.g., new sex partner or multiple sex partners)

From the 2006 CDC STD Treatment Guidelines:

“Annual screening of all sexually active women aged  $\leq 25$  years is recommended, as is screening of older women with risk factors (e.g., those who have a new sex partner or multiple sex partners)... Evidence is insufficient to recommend routine screening for *C. trachomatis* in sexually active young men, based on feasibility, efficacy, and cost-effectiveness. However, screening of sexually active young men should be considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, correctional facilities, and STD clinics).”

“Clinicians and health care agencies should consider advising all women with chlamydial infection to be retested approximately 3 months after treatment. Providers are strongly encouraged to retest all women treated for chlamydial infection whenever they next seek medical care within the following 3–12 months, regardless of whether the patient believes that her sex partners were treated. Recognizing that retesting is distinct from a test-of-cure, as discussed in this report, is vital. Limited evidence is available on the benefit of retesting for chlamydia in men previously infected; however, some specialists suggest retesting men approximately 3 months after treatment.”

\*Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55(No. RR-11):38,40. <http://www.cdc.gov/std/treatment/>

**Gonorrhea:**

No current CDC guidelines exist.

From the 2006 CDC STD Treatment Guidelines\*:

“Because gonococcal infections among women frequently are asymptomatic, an essential component of gonorrhea control in the United States continues to be the screening of women at high risk for STDs. The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians screen all sexually active women, including those who are pregnant, for gonorrhea infection if they are at increased risk\*\*. Women aged <25 years are at highest risk for gonorrhea infection. Other risk factors for gonorrhea include a previous gonorrhea infection, other sexually transmitted infections, new or multiple sex partners, inconsistent condom use, commercial sex work, and drug use. The prevalence of gonorrhea infection varies widely among communities and patient populations. The USPSTF does not recommend screening for gonorrhea in men and women who are at low risk for infection.”

“Clinicians should consider advising all patients with gonorrhea to be retested 3 months after treatment. If patients do not seek medical care for retesting in 3 months, providers are encouraged to test these patients whenever they next seek medical care within the following 12 months, regardless of whether the patient believes that their sex partners were treated.”

\*Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55(No. RR-11):42,45. <http://www.cdc.gov/std/treatment/>

\*\*U.S. Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005;3:263–7.

## II. Test Types

<i>Valid Chlamydia Test Types</i>			
<b>Common name (method)</b>	<b>Manufacturer</b>	<b>Test brand name</b>	<b>CT or CT/GC</b>
Transcription Mediated Amplification (TMA)	Gen-Probe	Aptima Combo 2 Assay	CT/GC
Strand Displacement Amplification (SDA)	Becton Dickinson	BDProbeTec ET System	CT/GC
Polymerase Chain Reaction (PCR)	Roche	Amplicor CT/NG	CT/GC
Polymerase Chain Reaction (PCR)	Roche	COBAS Amplicor CT/NG	CT/GC
Nucleic Acid Hybridization	Gen-Probe	PACE 2C CT/GC	CT/GC
Signal Amplification	Digene	Hybrid Capture 2 CT/GC DNA Test	CT/GC
Transcription Mediated Amplification (TMA)	Gen-Probe	Aptima CT Assay	CT
Polymerase Chain Reaction (PCR)	Roche	Amplicor CT	CT
Polymerase Chain Reaction (PCR)	Roche	COBAS Amplicor CT	CT
Strand Displacement Amplification (SDA)	Becton Dickinson	BDProbeTec ET System	CT
Nucleic Acid Hybridization	Gen-Probe	PACE 2 CT	CT
Enzyme Immunoassay (EIA)	Various	Various	CT
Direct Florescent Assay (DFA)	Various	Various	CT
Culture	Various	Various	CT

<i>Valid Gonorrhea Test Types</i>			
<b>Common name (method)</b>	<b>Manufacturer</b>	<b>Test brand name</b>	<b>GC or CT/GC</b>
Transcription Mediated Amplification (TMA)	Gen-Probe	Aptima Combo 2 Assay	CT/GC
Strand Displacement Amplification (SDA)	Becton Dickinson	BDProbeTec ET System	CT/GC
Polymerase Chain Reaction (PCR)	Roche	Amplicor CT/NG	CT/GC
Polymerase Chain Reaction (PCR)	Roche	COBAS Amplicor CT/NG	CT/GC
Nucleic Acid Hybridization	Gen-Probe	PACE 2C CT/GC	CT/GC
Signal Amplification	Digene	Hybrid Capture 2 CT/GC DNA Test	CT/GC
Transcription Mediated Amplification (TMA)	Gen-Probe	Aptima GC Assay	GC
Nucleic Acid Hybridization	Gen-Probe	PACE 2 GC	GC
Polymerase Chain Reaction (PCR)	Roche	Amplicor NG	GC
Polymerase Chain Reaction (PCR)	Roche	COBAS Amplicor NG	GC
Strand Displacement Amplification (SDA)	Becton Dickinson	BDProbeTec ET System	GC
Culture	Various	Various	GC

### III. Core IPP Data Elements

Field Name	Type	Length	Description	Valid Values/Definitions
region	C	2	The HHS region submitting the record.	01-Region 1 02-Region 2 03-Region 3 04-Region 4 05-Region 5 06-Region 6 07-Region 7 08-Region 8 09-Region 9 10-Region 10
quarter	C	1	The time period during which the test was conducted.	0-End of Year 1-Quarter 1 2-Quarter 2 3-Quarter 3 4-Quarter 4
year	C	4	The year during which the test was conducted.	YYYY format Valid value range: 1988 - present
state_code	C	2	The person's state GNIS code of residence.	2-digit code identifying state. Refer to: <a href="http://geonames.usgs.gov/domestic/index.html">http://geonames.usgs.gov/domestic/index.html</a> <i>See Section VII for more detailed information</i>
county_code	C	3	The person's county GNIS code of residence.	3-digit code identifying county. Refer to: <a href="http://geonames.usgs.gov/domestic/index.html">http://geonames.usgs.gov/domestic/index.html</a>
birth_dt	D		The person's date of birth.	Date variable type
age	C	2	The age of the person at the time the test was conducted. This variable is reported by the region and may be based on self-report or regional calculation.	Valid value range: 00 - 99 Unknown values are left blank
calculated_age	C	2	The calculated age of the patient at the time the test was conducted. This variable is calculated at CDC (specimen date – date of birth).	Valid value range: 00 - 99 Invalid or unknown values are left blank

Field Name	Type	Length	Description	Valid Values/Definitions
sex	C	1	The biological sex of the person.	1-Male 2-Female 9-Unknown
race_a	C	1	The person's self-reported race is Asian	1-Yes
race_i	C	1	The person's self-reported race is American Indian/ Alaska Native.	1-Yes
race_b	C	1	The person's self-reported race is African American/ Black.	1-Yes
race_p	C	1	The person's self-reported race is Pacific Islander/ Native Hawaiian.	1-Yes
race_w	C	1	The person's self-reported race is White.	1-Yes
race_o	C	1	The person's self-reported race is Other.	1-Yes
race_r	C	1	The person refused to report race.	1-Yes (person refused to report race)
race_u	C	1	The person could not provide information regarding their race.	1-Yes (person could not provide information regarding their race)
ethnicity	C	1	The person's self-reported ethnicity is Hispanic or Latino.	1-Yes, Hispanic or Latino 2-No, not Hispanic or Latino 9-Unknown
specimen_source	C	2	The source of the specimen used to conduct the test.	01- Cervix/Endocervix 05- Oropharynx 07- Other 09- Rectum 10- Urethra 11- Urine 12- Vagina 99- Unknown
specimen_dt	D		The date the specimen was collected.	Date variable type
facility_id	C	22	The health care provider or facility identification number.	Format varies by region
visit_type	C	1	If the facility type is an integrated clinic (facility_type on Facility Reference File="27"), the type of visit that occurred.	1- Family Planning 2- STD 3- Prenatal 4- Other 9- Not applicable

Field Name	Type	Length	Description	Valid Values/Definitions
facility_link_id	C	24	A facility identifier that links the facility to the Facility Reference File, which contains additional information about the facility.	Format varies by region, although often times a combination of state and facility_id
lab_id	C	20	The laboratory identification number.	Format varies by region.
ct_test_type	C	4	The type of chlamydia test (laboratory technology).	Method/Manufacturer/Brand Name 17.1- TMA/GP/Aptima Combo 2CT/GC 18.1- SDA/BD/BDProbeTec CT/GC 19.1- PCR/Roche/Amplicor CT/GC 19.2- PCR/Roche/COBAS CT/GC 20- Nucleic Acid Hybrid./GP/PACE 2CT/GC 21- Signal Amplification/Digene/Hybrid Capture 2 CT/GC DNA 09.1- TMA/GP/Aptima CT 06.1- PCR/Roche/Amplicor CT 06.2- PCR/Roche/COBAS Amplicor CT 08.1- SDA/BD/BDProbeTec CT 05.1- Nucleic Acid Hybrid./GP/PACE 2CT 04- EIA 03- DFA 02- Culture 88- Other (Please inform CDC if this code is used) 99- Unknown (Test type not specified or otherwise unavailable)
ct_test_rslt	C	1	The chlamydia test result.	1-Positive 2-Negative 3-Indeterminate 9-Unknown

Field Name	Type	Length	Description	Valid Values/Definitions
gc_test_type	C	4	The type of gonorrhea test (laboratory technology).	Method/Manufacturer/Brand Name 17.1- TMA/GP/Aptima Combo 2CT/GC 18.1- SDA/BD/BDProbeTec CT/GC 19.1- PCR/Roche/Amplicor CT/GC 19.2- PCR/Roche/COBAS Amplicor CT/GC 20- Nucleic Acid Hybrid./GP/PACE 2CT/GC 21- Signal Amplification/Digene/Hybrid Capture 2 CT/GC DNA 16.1- TMA/GP/Aptima GC 11.1- Nucleic Acid Hybrid./GP/PACE 2GC 12.1- PCR/Roche/Amplicor GC 12.2- PCR/Roche/COBAS Amplicor NG 15.1- SDA/BD/BDProbeTec GC 10- Culture 88- Other (Please inform CDC if this code is used) 99- Unknown (Test type not specified or otherwise unavailable)
gc_test_rslt	C	1	The gonorrhea test result.	1-Positive 2-Negative 3-Indeterminate 9-Unknown

*Field Name:* Actual variable name as found in dataset

*Type:* C=character; D=date

*Length:* Length of field as stored in dataset

*Description:* Full explanation of field

*Valid Values and Value Definitions:* Code stored in database followed by full definition of code value

#### IV. Enhanced IPP Data Elements

*To be addressed at a later time.*

#### V. Facility Reference File

##### Core Variables

Field Name	Type	Length	Description	Valid Values/Definitions
------------	------	--------	-------------	--------------------------

Field Name	Type	Length	Description	Valid Values/Definitions
facility_link_id	C	24	An facility identifier that links the facility to the primary dataset, which contains line-listed test results.	Format varies by region, although often times a combination of state and facility_id
facility_id	C	22	The health care provider or facility identification number.	Format varies by region
facility_name	C	100	The health care provider or facility name.	Text name of facility
facility_type	C	2	The health care provider or facility type.	01-HIV Counseling and Testing Site 02-STD 03-Drug Treatment 04-Family Planning 07-Other Health Department Clinic 08-Private Physician/HMO 10- Hospital - Emergency Room (ER), Urgent care facility 14-Labor and Delivery 15-Prenatal 16-National Job Training Program 17-School-based clinic 18-Mental Health Provider 19-Adult Correctional Facility 20-Juvenile Correctional Facility 21-Adolescent/Teen Clinic 22-Alternative/Outreach Settings 23-Homeless Shelter 24-Community Health Center 25-HIV Clinic 26-University/College Health Center 27-Integrated Clinic 28-School Screening 29- Hospital - Other 66-Indian Health Service 77-Military 88-Other <i>See section VII for more detailed information</i>

Field Name	Type	Length	Description	Valid Values/Definitions
facility_city_code	C	6	The facility GNIS city code.	6-digit code identifying city. Refer to: <a href="http://geonames.usgs.gov/domestic/index.html">http://geonames.usgs.gov/domestic/index.html</a> Note: Regions are not required to implement GNIS for cities. If not using GNIS, please provide a description of codes used in regional codebook.
facility_city_name	C	100	The facility city name.	Text name of city
facility_county_code	C	3	The facility GNIS county code.	3-digit code identifying county. Refer to: <a href="http://geonames.usgs.gov/domestic/index.html">http://geonames.usgs.gov/domestic/index.html</a>
facility_county_name	C	100	The facility county name.	Text name of county
facility_state_code	C	2	The facility GNIS state code.	2-digit code identifying state. Refer to: <a href="http://geonames.usgs.gov/domestic/index.html">http://geonames.usgs.gov/domestic/index.html</a> <i>See Section 3 for more detailed information</i>
facility_state_postal	C	2	The facility state postal abbreviation.	2-character alpha postal code <i>See Section 3 for more detailed information</i>
facility_zip_code	C	5	The facility zip code.	5-digit code. Refer to: <a href="http://www.usps.gov">http://www.usps.gov</a>

### Enhanced Variables

*To be addressed at a later time.*

## VI. CDC Data Submission Process

CDC receives data from each region on a quarterly basis, as well as an annual end-of-year data file. The preferred format for data submission is in a SAS database format (.sd2 or .sas7bdat). If regions are unable to send SAS data to CDC, CDC will accept data in other formats, given that (1) SAS can read the data file (SAS can read most data files) and (2) the data are in the format (variable names, values, types, lengths) specified in this codebook. Data should be encrypted and submitted via the CDC FTP site.

Regional Coordinators may obtain a valid SAS license from CDC. To obtain a SAS license, contact Sharon Clanton ([sclanton@cdc.gov](mailto:sclanton@cdc.gov)) in the Statistics and Data Management Branch (CDC/NCHSTP/DSTDP). Instructions for FTP site usage (and encryption) are located in *Encryption and FTP Site Usage (IPP).doc*.

### Reporting Schedule

Period Covered	Due to CDC	File Naming Conventions*	
		Prevalence Dataset	Facility Reference File
(Quarter 1) January 1-March 31	May 15	P_2007Q1_R01	F_2007Q1_R01
(Quarter 2) April 1-June 30	August 15	P_2007Q2_R01	F_2007Q2_R01
(Quarter 3) July 1-September 30	November 15	P_2007Q3_R01	F_2007Q3_R01
(Quarter 4) October 1-December 31	February 15	P_2007Q4_R01	F_2007Q4_R01
(End Year) January 1-December 31	April 15	P_2007EY_R01	F_2007EY_R01

\* 2007, Region I used as an example

P=Prevalence; F=Facility (Facility Reference File); Q=Quarter; EY=End Year; R=Region

## Additional Data Definitions

### Facility Type

Value	Name	Description
01	HIV Counseling and Testing Site	A site whose primary mission is dedicated to providing counseling and HIV testing services.
02	Sexually Transmitted Disease (STD) Clinic	A clinic whose primary mission is to provide diagnosis, treatment, counseling, and sex partner notification for sexually transmitted diseases.
03	Drug Treatment	A residential or outpatient clinic whose primary mission is to provide treatment for drug, alcohol, and other substance abuse.
04	Family Planning Clinic	A clinic whose primary mission is to provide contraceptive and reproductive health care for the prevention and achievement of pregnancy. Such sites receive federal and/or state family planning funds and are situated in state or county health departments or are community-based organizations (may include Title X and non-Title X funded facilities, including Planned Parenthood clinics).
07	Other Health Department Clinic	A public clinic administered by a local or state health department that can not be classified in one of the other defined disease or medical service-specific facility types.
08	Private Physician/ HMO	A non-publicly funded group of health care providers or an individual health care provider who provides medical care (e.g., general/family/internal medicine practitioners, pediatricians).
10	Hospital - Emergency Room (ER), Urgent care facility	A department in a hospital or clinic staffed and equipped to provide emergency care to persons requiring immediate medical treatment.
14	Labor and Delivery	A facility providing health care services to women during labor and delivery through birth of the infant.
15	Prenatal Clinic	A clinic whose primary mission is to provide health care and education to pregnant women.
16	National Job Training Program	A residential, educational, and job training program for at-risk youth aged 16 to 24 years. Job Corps is a public-private partnership administered by the U.S. Department of Labor and the Employment and Training Administration.
17	School-Based Clinic	A clinic located in or affiliated with a middle school, junior high school, senior high school, or other type of school providing education at or below 12 <sup>th</sup> grade that provides medical care and health education to students.
18	Mental Health Provider	Facility or provider providing inpatient or outpatient mental health services.
19	Adult Correctional Facility	A prison, jail, detention center, or other correctional facility where persons aged 18 years and older are incarcerated or supervised by the criminal justice system.

<b>Value</b>	<b>Name</b>	<b>Description</b>
20	Juvenile Correctional Facility	A prison, jail, detention center, or other correctional facility where persons aged 17 years and younger are incarcerated or supervised by the criminal justice system.
21	Adolescent/Teen Clinic	A clinic whose primary mission is to provide medical and social services to adolescents aged 10-19 years and is not affiliated with a school- or university-based health clinic.
22	Alternate/Outreach Settings	Medical services that are provided by a mobile van or at locations that change frequently or are non-traditional health care locations (e.g., public housing settings or recreation center settings).
23	Homeless Shelter	A public or private facility whose primary mission is to provide services (including health care) to homeless individuals.
24	Community Health Center	A facility whose primary mission is to provide primary and preventive health care services in medically-underserved areas throughout the U.S. Rural Health Centers/Clinics are included in this category.
25	HIV Clinic	A clinic whose primary mission is to provide HIV primary care.
26	University/College Health Center	A clinic operated by a college or university whose primary mission is to provide health care for enrolled students.
27	Integrated Clinic	A site that provides both family planning and STD services, in addition to other services, to any patient at any time. (Note: the 'visit type' variable must be used to differentiate family planning, STD, prenatal and "other" clients.)
28	School Screening	Testing occurs as part of a screening program in a junior high, high school, university, or other formal educational setting, such as charter schools, where the provision of a test is not contingent upon a student seeking care at a school-based health clinic. (This code should be used only for school screening programs, not for student health centers or school-based clinics).
29	Hospital - Other	A multidisciplinary public or private facility that provides non-emergency inpatient or outpatient medical services. Includes specialty clinics within a hospital ( <b>Excludes</b> care sites that provide emergency or urgent care and obstetric or labor and delivery services).
66	Indian Health Services	A facility funded as part of the Indian Health Services.
77	Military	A facility operated by the U.S. military whose primary mission is to provide health care.
88	Other	A clinic that can not be categorized in any of the other defined facility types.

### State Formats

	<u>\$STATE_POSTAL_F</u>	<u>\$STATE_CODE_F</u>			<u>\$STATE_POSTAL_F</u>	<u>\$STATE_CODE_F</u>
Alabama	AL	01		North Carolina	NC	37
Alaska	AK	02		North Dakota	ND	38
Arkansas	AR	05		Nebraska	NE	31
Arizona	AZ	04		New Hampshire	NH	33
California	CA	06		New Jersey	NJ	34
Colorado	CO	08		New Mexico	NM	35
Connecticut	CT	09		Nevada	NV	32
Delaware	DE	10		New York	NY	36
Florida	FL	12		Ohio	OH	39
Georgia	GA	13		Oklahoma	OK	40
Hawaii	HI	15		Oregon	OR	41
Iowa	IA	19		Pennsylvania	PA	42
Idaho	ID	16		Rhode Island	RI	44
Illinois	IL	17		South Carolina	SC	45
Indiana	IN	18		South Dakota	SD	46
Kansas	KS	20		Tennessee	TN	47
Kentucky	KY	21		Texas	TX	48
Louisiana	LA	22		Utah	UT	49
Massachusetts	MA	25		Virginia	VA	51
Maryland	MD	24		Vermont	VT	50
Maine	ME	23		Washington	WA	53
Michigan	MI	26		Wisconsin	WI	55
Minnesota	MN	27		West Virginia	WV	54
Missouri	MO	29		Wyoming	WY	56
Mississippi	MS	28		District of Columbia	DC	11
Montana	MT	30		Puerto Rico	PR	72
				Virgin Islands	VI	78